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Does right ventricular pacing increase the risk  
of ventricular arrhythmias in patients with  
an implantable cardioverter-defibrillator?
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INTRODUCTION
The use of therapy with implantable cardioverter-defibrillators 
(ICD) allows for significant improvement in survival in patients 
with systolic heart failure (HF), reducing both the incidence 
of sudden cardiac death and all-cause mortality [1–3]. Cur-
rently available devices, in addition to the discontinuation of 
life-threatening ventricular arrhythmias such as ventricular 
tachycardia (VT) and ventricular fibrillation (VF), also have the 
function of right ventricular (RV) pacing, which is particularly 
useful for the prevention of significant bradycardia in the 
period after discharge. 
However, findings from clinical studies about pacemakers 
or ICD indicate that RV pacing in patients with left ventricu-
lar (LV) systolic dysfunction is associated with an increased 
risk of HF, increasing the frequency of hospitalisation and 
possibly death from this cause [4–6]. This effect may in part 
be responsible for the observed shift, in the era of the ICD, 
in the causes of death among patients with systolic HF, who 
currently most often die because of HF, while the arrhythmic 
death rate compared to previous observations has decreased 
[7]. But there are also reports suggesting that RV pacing with 
ICD may promote the occurrence of VT/VF episodes, requiring 
intervention of the device, which also would contribute to 
a possible increase in mortality and thereby reduce the prog-
nostic benefits of ICD therapy [4, 5]. This problem seems to be 
very important, especially since a different number of episodes 
of ventricular pacing with an ICD may also occur in patients 
who do not have indications for permanent pacing. Patients 
with HF are in this regard particularly vulnerable, because due 
to the structural damage of the heart and the chrono- and 
dromotropic negative impacts of used beta-blockers and/or 
amiodarone, they are exposed to automatism and conduction 
disorders which facilitate RV pacing.
RIGHT VENTRICULAR PACING AND  
THE OCCURRENCE OF VT/VF EPISODES
The possibility of harmful effects of RV pacing in patients with 
reduced LV systolic function with an ICD was pointed out after 
the announcement of the results of the Dual Chamber and 
VVI Implantable Defibrillator study (DAVID) which compared 
the effects between the application of a dual-chamber device 
programmed to DDDR mode with a base rate of 70/min, and 
a single-chamber device programmed to VVI 40/min mode, 
in a group of 506 patients with systolic HF. During this ob-
servation (median of 8.4 months), a higher incidence of the 
combined endpoint including death and hospitalisation for 
HF in patients with dual-chamber pacing was noticed, and 
a post-hoc analysis of the collected data showed that the 
reason for this was a much higher incidence of RV pacing in 
this group of patients [8, 9]. It should be noted that this group 
consisted of patients without indications for permanent pac-
ing, so RV pacing here was a somewhat unintentional side 
effect of DDD mode with a high base rate of stimulation. In 
this study, however, the possible influence of a high percent-
age of such stimulation on the occurrence of episodes of 
ventricular tachyarrhythmias was not investigated. However, 
further observations have provided these findings.
Smit et al. [10] analysed a group of 456 consecutive 
patients without overt HF, but most of them had mild LV 
systolic dysfunction (mean LV ejection fraction [LVEF] 40%), 
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who were implanted with an ICD. They found that an over-
all percentage of RV pacing > 50% was associated not only 
with a higher incidence of HF, but was also an independent 
predictor of ICD shocks. 25% of the surveyed patients expe-
rienced high-energy therapy, while in a subgroup stimulated 
over 50%, the interventions occurred in a larger number of 
patients (34% vs. 21%), and the time to the first intervention 
of device was shorter compared to the subgroup with the 
percentage of stimulation not exceeding 50% [10]. Post-hoc 
analysis of data from the MADIT II trial involving patients after 
myocardial infarction with LVEF ≤ 30% taking into account 
the 567 patients randomised to ICD implantation with known 
percentage of RV pacing also showed a higher probability 
of adequate ICD therapy (antitachyarrhythmic pacing and 
shocks) in the group stimulated at > 50% [4]. 
The results of these observations are very similar, despite 
significant differences in the characteristics of the examined 
populations. In the analysis of Smit et al. [10], patients with 
mild LV dysfunction receiving the ICD significantly prevailed 
in secondary prevention; in most cases, it was also a dual 
chamber system. The MADIT II trial involved patients with 
severe LV systolic dysfunction qualified for an ICD in primary 
prevention, and dual chamber systems were implanted in 46% 
of patients [4, 10]. It seems that a large amount of RV pacing 
in a population of patients with implanted ICD and reduced 
LV systolic function has not only the previously known adverse 
effect of favouring the progression of HF, but also has a clear 
pro-arrhythmic effect. 
It is not clear what exact proportion of such stimula-
tion is enough to induce the above-mentioned detrimental 
effects. In these observations, 50% was taken as the cut-off 
value, but the analysis of the distribution of the percentage 
of ventricular pacing in the surveyed populations indicates 
that, in fact, patients hardly stimulated were comparable 
(median of stimulation in stimulated subgroups ≤ 50% — 0% 
in the study of Smit et al. [10], and 0.2% in the analysis of 
data from MADIT II [4]) with those stimulated almost com-
pletely (medians of percentage of stimulation in stimulated 
subgroups > 50%, 96% and 95.6%, respectively). The study 
by Gardiwal et al. [11] provides relevant information in this 
regard. It evaluates the impact of the total percentage of RV 
pacing on the incidence of episodes of VT/VF in the group 
of 245 patients with implanted ICD, mainly in secondary 
prevention. In this case, the researchers assumed a very 
low cut-off point of 2% only, and found that in a stimulated 
group > 2% the time to first occurrence of arrhythmia was 
significantly shorter than in a stimulated group ≥ 2%, and the 
percentage of stimulation exceeding this cut-off point was an 
independent predictor of occurrence of VT/VF. Moreover, the 
incidence of arrhythmic episodes increased with an increase 
in the frequency of ventricular pacing in the overall surveyed 
population. On this basis, it can be assumed that a very small 
amount of ventricular pacing, and perhaps any RV pacing in 
patients with an implanted ICD, acts in an arrhythmogenic 
way and that the higher the percentage of stimulation, the 
greater the risk of incidents of serious ventricular tachyar-
rhythmias and intervention of the device. Some doubt as 
to the validity of this thesis may indeed occur during the 
analysis of the retrospective results of a subgroup of 715 pa-
tients from the INTRINSIC RV trial, published by Olshansky 
et al. [12], which suggest that a moderate percentage of RV 
pacing (10–19%) may be more favourable, i.e. giving both 
a lower risk of death and hospitalisation for HF and a lower 
incidence of ICD shocks than a very low percentage (0–9%). 
This study, however, included only patients with an implanted 
dual chamber ICD system programmed in DDDR mode, and 
the authors took into account the shocks and not, as in most 
studies, all VT/VF episodes, interrupted by the ICD. It seems 
that the main reason for these somewhat different conclu-
sions are methodological differences, although it is possible 
that for some patients some amount of RV pacing ensuring 
restoration of normal atrioventricular synchrony could bring 
some benefits. There are also reports that undermine the 
relationship between the stimulation of the right ventricle 
and the incidence of episodes of ventricular arrhythmia. 
Stockburger et al. [13] analysed a group of 213 patients with 
HF, who had an ICD implanted, and they did not notice that 
the cumulative percentage of ventricular pacing equal to or in 
excess of 30% was associated with an increased occurrence 
of of VT/VF incidents.
However, this result should be treated with caution, since 
it may result from the fact that this study surveyed subgroups 
that differed significantly, taking into account the number of 
patients (the stimulated group ≥ 30% had only 24 persons, 
while the stimulated group < 30% consisted of 189 people), 
and the combined percentage of ventricular pacing in the total 
population was in general very low (median 0%, interquartile 
range 0–2.5%).
In summary, it is clear that most observations seem to 
favour the proarrhythmic effects of RV pacing in patients with 
an implanted ICD. Moreover, as the results of the prolonged 
eight-year observation of patients included in the MADIT-II 
trial demonstrate, this effect may be a secondary, after worsen-
ing HF, cause of adverse impact of RV pacing, which leads to 
a significant reduction of benefits from therapy using ICD [5].
POSSIBLE MECHANISMS OF PROARRHYTHMIC 
ACTION OF RIGHT VENTRICULAR PACING
Stimulation of the right ventricle, causing abnormal, similar 
sequence of electrical activation of the muscle in ventricles 
of the heart as in the native block of left bundle branch, 
leads to the mechanical dyssynchrony of the contraction of 
the heart muscle and associated load variation of individual 
segments. Stress of the heart wall becomes the greatest within 
the lateral segments of the left ventricle, which are activated 
at the latest, because of the impact of the early contraction 
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of the interventricular septum, and the activation of this area 
during the end-systolic period when consequent load is the 
greatest. These changes can lead to atioasymmetrical hyper-
trophy of the LV muscle and disturbance of perfusion and 
oxygen utilisation in the myocardium (the increase in areas 
of late activation, the decrease in areas activated early), and 
also to regional changes in autonomic innervation [14, 15]. In 
addition, the secondary, in comparison to dyssynchony, load 
polarisation of individual areas of the left ventricle can induce 
changes in the expression of multiple proteins in cardiomyo-
cytes, including those involved in the processes connected to 
the formation of arrhythmia, i.e. in the regulation of calcium 
homeostasis and the conduction of electrical impulses. In an 
experimental model, stimulation of right ventricle caused a sig-
nificant decrease in the expression of ATP-ase of sarcoplasmic 
reticulum (SERCA2a), phospholamban and connexin 43 in 
the lateral wall of the left ventricle [16]. Reduced expression 
of connexin 43, which is the main protein of intercellular 
connections within the myocardium, in several observations, 
significantly increased susceptibility to ventricular arrhythmias, 
probably as a result of a one-way slowing down of conductivity 
and facilitation  of the creation and circulation of any reentrant 
wave [17, 18]. The occurrence of ventricular arrhythmias may 
be also favoured by other above-mentioned abnormalities. 
However, it seems that the development of potentially 
arrhythmogenic structural changes in the heart muscle requires 
a rather high percentage of RV stimulation. In stimulation with 
relatively low, or very low, frequencies, other mechanisms 
are probably involved. Himmrich et al. [19] pointed out the 
possibility of the induction of VT/VF, even by a single paced 
beat, caused by sudden changes in the length of cycle of 
rhythm of ventricles.
If the sinus rhythm is disturbed with a single prema-
ture beat, followed by a compensatory pause, then inter-
rupted with a paced ventricular beat, the sequence of 
a short-long-short RR interval period is created, causing the 
dispersion of refraction periods within the muscle of the ven-
tricle, which in favourable conditions might be the basis of 
arrhythmia, in particular, polymorphic ventricular tachycardia. 
In patients with anatomical substrate of ventricular arrhyth-
mias in a post-infarction scar, the pause belonging to such 
a sequence can also favour the creation of functional block 
in one arm of a potential loop of tachycardia, while ending 
it the paced ventricular beat is being conducted through the 
other arm and at the end of the refractory period in the first 
arm returns, initiating VT in a reentry mechanism. 
The aforementioned researchers observed episodes of 
ventricular tachyarrhythmia  induced with ventricular pacing 
(PIT — pacemaker-induced ventricular tachycardia) in 26% of 
the 150 analysed patients with an implanted single-chamber 
ICD who had no indication for permanent pacing, but in 
8.6% of patients, these were the only type of VT/VF episode. 
In the latter subgroup, the total exclusion of ventricular pacing 
resulted in the complete disappearance of episodes of arrhyth-
mia, confirming their causality to unintended stimulation of 
ventricle with ICD [19]. Possible participation of the described 
mechanism in arrythmogenic effect of stimulation of the right 
ventricle is also confirmed by observations by Sweeney et al. 
[20], who analysed data concerning 136 episodes of VT/VF 
observed in 204 patients covered in the PainFREE Rx II and 
Entrust trial, and stated that incidents corresponding to PIT 
occurred in 3–5% of all patients, and formed, depending on 
the stimulation mode, 2.6–5.2% of all episodes of arrhythmia.
CONCLUSIONS
Many findings indicate an adverse proarrhythmic effect 
of RV pacing in the population of patients eligible for im-
planting a ICD. Such stimulation may increase the risk of 
serious ventricular arrhythmias requiring ICD intervention, 
including high-energy therapy which worsen prognosis and 
quality of life, leading to a reduction of the benefits from an 
implanted ICD. Therefore, in this case it seems fully justified 
to recommend limiting RV pacing. For patients who do not 
require pacing, the best solution seems to be implantation of 
a single-chamber system programmed to VVI mode with a very 
low basic pacing rate or hysteresis of heart rate. Implantation 
of a dual-chamber device may be justified in patients with 
dysfunction of the sinus node requiring atrial pacing, but in 
this case, close attention must be paid to the possibility of 
unintentional stimulation of the right ventricle which should be 
maximally reduced with the support of algorithms promoting 
own atrioventricular conduction or enabling changes between 
DDD and AAI modes. For patients requiring ventricular pacing 
due to impaired atrioventricular conduction, implantation of 
an ICD with the function of cardiac resynchronisation therapy 
should be considered (or an upgrade to such a system in 
patients with an already implanted device), but it must be 
borne in mind that the benefits from this strategy are suffi-
ciently documented only in terms of the reduction of the risk 
of progression of HF. The issue of a reduction in the number 
of episodes of VT/VF has not yet been clearly defined, and is 
still a matter of controversy.
This is reflected in the current European Society of Car-
diology guidelines on HF, which recommend  implantation 
of the cardiac resynchronisation therapy (CRT) system in 
patients with LV systolic dysfunction and an indication for 
permanent cardiac pacing, in NYHA III or IV functional class 
(Class IIa) and NYHA II (class IIb) only to reduce the risk of 
worsening of HF [21]. 
Biventricular pacing improves the uniformity of LV activa-
tion and reduces imbalance within the autonomic system, so 
it should reduce the risk of ventricular arrhythmias [22]. But, 
so far, a reduction in the number of VT/VF episodes after the 
upgrade of the ICD to CRT-D has only been observed in single 
studies, involving only small groups of patients [23, 24]. Results 
of other observations, including large clinical trials such as 
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MIRACLE ICD and REVERSE, did not show significant differ-
ences in the number of interventions of devices because of ven-
tricular arrhythmias between the groups of patients with an ICD 
and ICD-CRT [25, 26]. Moreover, Thijssen et al. [27] analysed 
a group of 115 patients whose ICD system was upgraded by 
adding the function of resynchronisation due to progression of 
HF, and they noticed no significant decline in adequate therapy 
from the device in the surveyed population. The trend in this 
direction was present only among those in whom a response to 
CRT expressed in a decrease of end-systolic volume of the left 
ventricle has been observed, whereas patients not responding 
to resynchronisation experienced ICD interventions even more 
often than before replacing the device. 
Perhaps, at least in some cases, when no improvement in 
the remodelling and function of the left ventricle is reached 
after CRT implantation, the proarrhythmic effect of stimulation 
from the branches of the coronary sinus predominates. This 
effect may be related to the reversed direction (i.e. from the 
epicardium to the endocardium) of depolarisation within 
the walls of the ventricle and the subsequently increased 
transmural dispersion of repolarisation.
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